Tính miễn dịch của các chất ức chế TNF dưới da và ý nghĩa lâm sàng của nó trong bối cảnh thực tế ở bệnh nhân viêm khớp liên quan đến cột sống

de Vries MK, Wolbink GJ, Stapel SO et al (2007) Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66:1252–1254 Méric J-C, Mulleman D, Ducourau E et al (2011) Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study. Ther Drug Monit 33:411–416 Ducourau E, Mulleman D, Paintaud G et al (2011) Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 13(3):R105 Plasencia C, Pascual-Salcedo D, Nuño L et al (2012) Influence of immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximab. Ann Rheum Dis 71:1955–1960 de Vries MK, Brouwer E, van der Horst-Bruinsma IE et al (2009) Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 68:1787–1788 Kneepkens EL, Wei JC, Nurmohamed MT et al (2015) Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Ann Rheum Dis 74:396–401 Ducourau E, Rispens T, Samain M, Dernis E, Le Guilchard F, Andras L, Perdriger A, Lespessailles E, Martin A, Cormier G, Armingeat T, Devauchelle-Pensec V, Gervais E, Le Goff B, de Vries A, Piver E, Paintaud G, Desvignes C, Ternant D, Watier H, Goupille P, Mulleman D (2020) Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomized trial. RMD Open 6(1):001047. https://doi.org/10.1136/rmdopen-2019-001047 Paramarta JE, Baeten DL (2014) Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation. Arthritis Res Ther 16(4):R160 Cludts I, Spinelli RF, Morello F, Hockley J, Valesini G, Wadhwa M (2018) Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab. Cytokine 101:70–77 Maneiro JR, Salgado E, Gomez-Reino JJ (2013) Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune- mediated inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med 173(15):1416–1428 Spinelli FR, Valesini G (2013) Immunogenicity of anti-tumor necrosis factor drugs in rheumatic diseases. Clin Exp Rheumatol 31(6):954–963 Bornstein G, Lidar M, Langevitz P et al (2018) The prevalence and clinical effect of immunogenicity of TNF (alpha) blockers in patients with axial SpA. Clin Exp Rheumatol 36:228–232 de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT et al (2009) Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 68:531–535 Deodhar A, Braun J, Inman RD et al (2015) Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis 74(4):757–761 Inman RD, Davis JC Jr, Heijde D et al (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58(11):3402–3412 Sieper J, van der Heijde D, Dougados M et al (2015) A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active non-radiographic axial spondyloarthritis. Arthritis Rheum 67(10):2702–2712 Sieper J, Landewé R, Rudwaleit M et al (2015) Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial. Arthritis Rheum 67(3):668–677 Jani M, Isaacs JD, Morgan AW (2016) High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2015-208849 Wolbink GJ, Voskuyl AE, Lems WF et al (2005) Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64(5):704–707 Pouw MF, Krieckaert CL, Nurmohamed MT et al (2015) Key findings towards optimizing adalimumab treatment: the concentration-effect curve. Ann Rheum Dis 74(3):513–518 Chen D-Y, Chen YM, Tsai W-C et al (2015) Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment. Ann Rheum Dis 74(3):e.16 Kneepkens EL, Plasencia C, Krieckaert CL et al (2014) Golimumab trough levels, anti-drug antibodies, and clinical response in patients with rheumatoid arthritis treated in daily clinical practice. Ann Rheum Dis 73(12):2217 Jani M, Chinoy H, Warren RB et al (2015) Clinical utility of random anti–tumor necrosis factor drug–level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheum 67(8):2011–2019 Goss SL, Klein CE, Jin Z et al (2018) Methotrexate dose in patients with early rheumatoid arthritis impacts methotrexate polyglutamate pharmacokinetics, adalimumab pharmacokinetics, and efficacy: pharmacokinetic and exposure-response analysis of the Concerto trial. Clin Ther 40:309–319 Krieckaert CL, Nurmohamed MT, Wolbink GJ (2012) Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 71:1914–1915 Krieckaert CLM, Bartelds GM, Lems WF, Wolbink GJ (2010) The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 12(5):217 Nam JL, Winthrop KL, van Vollenhoven RF et al (2010) Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69(6):976–986 Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA et al (2019) 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 71(10):1599–1613 Garcês S, Demengeot J, Benito-Garcia E (2013) The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 72(12):1947–1955 Pérez-Guijo VC, Cravo AR, Mdel CC, Font P, Muñoz-Gomariz E, Collantes-Estevez E (2007) Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 74:254–258 Mulleman D, Lauferon F, Wendling D et al (2011) Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. Arthritis Res Ther 13(3):R82 Breban M, Ravaud P, Claudepierre P et al (2008) Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 58:88–97 Lie E, Kristensen LE, Forsblad-d’Elia H, Zverkova-Sandström T, Askling J, Jacobsson LT, ARTIS Study Group (2015) The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum Dis 74(6):970–978 Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 12:2286–2291 Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A et al (2003) Assessment of enthesistis in ankylosing spondylitis. Ann Rheum Dis 62:127–132 Calin A, Garret S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285 Bendtzen K (2015) Immunogenicity of anti-TNF-α biotherapies: II. Clinical relevance of methods used for anti-drug antibody detection. Front Immunol 6:109 Ducourau E, Ternant D, Lequerré T et al (2014) Towards an individualized target concentration of adalimumab in rheumatoid arthritis. Ann Rheum Dis 73(7):1428–1429 Brunner H, Ruperto N, Tzaribachev N et al (2018) Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis 77(1):21–29 Gallego JMS, Rosas J, Marco-Mingot M et al (2019) Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis. Rheumatol Int 39(5):841–849 van Schouwenburg PA, van de Stadt LA, de Jong RN, van Buren EE, Kruithof S, de Groot E, Hart M, van Ham SM, Rispens T, Aarden L, Wolbink GJ, Wouters D (2013) Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralization. Ann Rheum Dis 72:104–109 Bartelds GM, Krieckaert CL, Nurmohamed MT et al (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305(14):1460–1468 Arends S, Lebbink HR, Spoorenberg A et al (2010) The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 28(5):661–668 van Schouwenburg PA, Rispens T, Wolbink GJ (2013) Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 9(3):164–172 Gehin JE, Goll GL, Warren DJ, Syversen SW, Sexton J, Strand EK, Kvien TK, Bolstad N, Lie E (2018) FRI0645 Anti-drug antibodies to certolizumab pegol are associated with low drug levels and reduced clinical response at 3 months in patients with inflammatory joint diseases. Data from the NOR-DMARD study. Ann Rheum Dis 77(Suppl 2):844 Rosas J, Llinares-Tello F, Senabre-Gallego JM et al (2017) Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis. Clin Exp Rheumatol 35(1):145–148 Micheroli R, Hebeisen M, Wildi LM, Exer P, Tamborrini G, Bernhard J, Möller B, Zufferey P, Nissen MJ, Scherer A, Ciurea A (2017) Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. Arthritis Res Ther 19(1):164 Gremese E, Bernardi S, Bonazza S, Nowik M, Peluso G, Massara A, Tolusso B, Messuti L, Miceli MC, Zoli A, Trotta F, Govoni M, Ferraccioli G (2014) Body weight, gender and response to TNF-α blockers in axial spondyloarthritis. Rheumatology 53(5):875–881 Singh S, Faggiorusso A, Singh AG et al (2018) Obesity and response to anti-tumor necrosis factor agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS ONE 13(5):e0195123 Kneepkens EL, Krieckaert CL, van der Kleij D et al (2015) Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. Ann Rheum Dis 74(10):1825–1829 Jamnitski A, Krieckaert CL, Nurmohamed MT et al (2012) Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 71(1):88–91 Pedersen L, Szecsi PB, Bjerrum PJ, Johansen PB (2020) Evaluation of therapeutic drug monitoring in the clinical management of patients with rheumatic diseases: data from a retrospective single-center cohort study. Biologics 14:115–125 Martín-López M, Carmona L, Balsa A, Calvo-Alén J, Sanmartí R, Tornero J, Rosas J (2018) Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review. Rheumatol Int 38(6):975–983. https://doi.org/10.1007/s00296-018-4022-4